MedTrace Logo

Laboratory Characteristics in Chronic Atrophic Acrodermatitis

NCT02147262 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-05-04

No results posted yet for this study

Summary

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with chronic atrophic dermatitis to gain better insight into pathogenesis of chronic infection with Borrelia burgdorferi sensu lato.

Conditions

  • Chronic Atrophic Acrodermatitis

Interventions

DRUG

doxycycline orally, 100 mg, bid, 14 days

DRUG

doxycycline orally, 100 mg, bid, 28 days

Sponsors & Collaborators

  • University of Ljubljana School of Medicine, Slovenia

    collaborator OTHER

  • Medical University of Vienna

    collaborator OTHER

  • Harvard University

    collaborator OTHER

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Franc Strle, MD, PhD · UMC Ljubljana

  • Dasa Stupica, MD, PhD · UMC Ljubljana

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Slovenia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147262 on ClinicalTrials.gov